Oxford, UK-based Summit Corp. plc has filed an F-1 with the SEC, seeking to raise $40 million in an initial public offering (IPO). The company said it plans to use the capital raised to help drive its clinical programs focused on Duchenne muscular dystrophy (DMD) and Clostridium difficile infection (CDI).